Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low molecular weight heparin for the prevention of severe preeclampsia: where next?

11 Dec 2017

Abstract excerpt

Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Maternal and fetal healthcare
Share to Pregnancy and preeclampsia studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29226532
DOI: 10.1111/bcp.13483

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low molecular weight heparin for the prevention of severe preeclampsia: where next?PMID 29226532Read ↗

Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunctionSemantic proximity Read ↗

Recent Advances in the Prevention and Screening of PreeclampsiaSemantic proximity Read ↗

Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.Semantic proximity Read ↗

ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--study protocol for a randomized controlled trial.Semantic proximity Read ↗

Pregnancy loss and thrombophilia: the elusive linkSemantic proximity Read ↗

Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during PregnancySemantic proximity Read ↗

Matrix Metalloproteinases as Drug Targets in PreeclampsiaSemantic proximity Read ↗

Low-dose aspirin prevents LPS-induced preeclampsia-like phenotype via AQP-1 and the MAPK/ERK 1/2 pathway.Semantic proximity Read ↗

LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signalingSemantic proximity Read ↗

Pilot study on the use of low molecular weight heparins in the prevention of thromboembolic disease during pregnancy and puerperiumSemantic proximity Read ↗

Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial.Semantic proximity Read ↗

Lessons From the EThIGII Trial: Proper Putative Benefit Assessment of Low-Molecular-Weight Heparin Treatment in M2/ANXA5 Haplotype Carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.